Seebri Breezhaler (glycopyrronium bromide)
- Region
- 🇪🇺 EU
- Active substance
- glycopyrronium bromide
- Company
- Novartis Europharm Limited
- Status
- Authorised
- Therapeutic area
- Pulmonary Disease, Chronic Obstructive
- EU approval
- Fri 28 Sep 2012
- Application
- EMEA/H/C/002430
- ATC
- R03BB06
- Official record
- www.ema.europa.eu
Indication
Seebri Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Trixeo Aerosphere Authorised · AstraZeneca AB
- 🇪🇺 Sialanar Authorised · Proveca Pharma Limited
- 🇪🇺 Enurev Breezhaler Withdrawn · Novartis Europharm Ltd
- 🇪🇺 Trimbow Authorised · Chiesi Farmaceutici S.p.A.
- 🇪🇺 Trydonis Authorised · Chiesi Farmaceutici S.p.A.
- 🇪🇺 Tovanor Breezhaler Authorised · Novartis Europharm Limited
- 🇪🇺 Enerzair Breezhaler Authorised · Novartis Europharm Limited
- 🇪🇺 Xoterna Breezhaler Authorised · Novartis Europharm Limited
- 🇪🇺 Ultibro Breezhaler Authorised · Novartis Europharm Limited
- 🇪🇺 Ulunar Breezhaler Authorised · Novartis Europharm Limited
Follow Seebri Breezhaler
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.